HK1202067A1 - Therapeutic agents comprising insulin amino acid sequences - Google Patents

Therapeutic agents comprising insulin amino acid sequences Download PDF

Info

Publication number
HK1202067A1
HK1202067A1 HK15102642.1A HK15102642A HK1202067A1 HK 1202067 A1 HK1202067 A1 HK 1202067A1 HK 15102642 A HK15102642 A HK 15102642A HK 1202067 A1 HK1202067 A1 HK 1202067A1
Authority
HK
Hong Kong
Prior art keywords
amino acid
acid sequences
therapeutic agents
insulin amino
acid sequence
Prior art date
Application number
HK15102642.1A
Other languages
English (en)
Chinese (zh)
Inventor
James Jowett
Christopher Woods
Christopher Prior
Original Assignee
Phasebio Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasebio Pharmaceuticals, Inc. filed Critical Phasebio Pharmaceuticals, Inc.
Publication of HK1202067A1 publication Critical patent/HK1202067A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK15102642.1A 2011-11-28 2012-11-28 Therapeutic agents comprising insulin amino acid sequences HK1202067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563985P 2011-11-28 2011-11-28
US201161563985P 2011-11-28
PCT/US2012/066795 WO2013082116A1 (en) 2011-11-28 2012-11-28 Therapeutic agents comprising insulin amino acid sequences

Publications (1)

Publication Number Publication Date
HK1202067A1 true HK1202067A1 (en) 2015-09-18

Family

ID=48536000

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102642.1A HK1202067A1 (en) 2011-11-28 2012-11-28 Therapeutic agents comprising insulin amino acid sequences

Country Status (14)

Country Link
US (2) US20130150291A1 (enExample)
EP (1) EP2785367A4 (enExample)
JP (1) JP2014534265A (enExample)
KR (1) KR20140103985A (enExample)
CN (1) CN104080473A (enExample)
AU (1) AU2012346058A1 (enExample)
BR (1) BR112014012789A2 (enExample)
CA (1) CA2856967A1 (enExample)
HK (1) HK1202067A1 (enExample)
IL (1) IL232781A0 (enExample)
MX (1) MX2014006391A (enExample)
RU (1) RU2014126244A (enExample)
SG (1) SG11201402661TA (enExample)
WO (1) WO2013082116A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
JP2016505627A (ja) * 2013-01-15 2016-02-25 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 治療剤、組成物、および血糖コントロールのための方法
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
WO2015178466A1 (ja) * 2014-05-21 2015-11-26 味の素株式会社 フィブロイン様タンパク質の製造法
AU2015349743B2 (en) * 2014-11-21 2021-06-10 Immunoforge Co., Ltd. ELP fusion proteins for controlled and sustained release
CA2976038A1 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
EP3124495A1 (en) * 2015-07-31 2017-02-01 Centre National de la Recherche Scientifique (C.N.R.S.) Derivatives of elastin-like polypeptides and uses thereof
CA2994279A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
CN105061566A (zh) * 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 拟胰岛素多肽及其应用
WO2017052305A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Method of insulin production
KR101815080B1 (ko) 2015-11-03 2018-01-04 재단법인대구경북과학기술원 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
SG11201805195YA (en) 2016-03-02 2018-07-30 Merz Pharma Gmbh & Co Kgaa Composition comprising botulinum toxin
WO2017189860A1 (en) 2016-04-27 2017-11-02 The Regents Of The University Of California Preparation of functional homocysteine residues in polypeptides and peptides
WO2017192449A1 (en) * 2016-05-06 2017-11-09 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
JP2020500150A (ja) * 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
US11220467B2 (en) 2017-01-11 2022-01-11 Recycle Track Systems, Inc. Indoor food waste fermentation and recycling process
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
CN111939244B (zh) 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
KR102456958B1 (ko) * 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
AU2020396647A1 (en) * 2019-12-06 2022-07-07 Ajinomoto Co., Inc. Method for producing peptide having physiological activity, and peptide comprising short linker

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826705T2 (de) * 1997-11-12 2006-02-23 Alza Corp., Palo Alto Verfahren zur dermalen verabreichung von polypeptiden
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US8334257B2 (en) * 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
BRPI0707796A2 (pt) * 2006-02-15 2011-05-10 Imclone Systems Inc formulaÇço, e, mÉtodo de tratamento
CN101616685B (zh) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 非结构化重组聚合物和其应用
EP3412300A1 (en) * 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
WO2010014689A1 (en) * 2008-07-29 2010-02-04 Phasebio Pharmaceuticals, Inc. Pharmaceutical formulations comprising elastin-like proteins
PT2459171T (pt) * 2009-07-31 2017-08-16 Sanofi Aventis Deutschland Composição de insulina de atuação longa
WO2011020091A1 (en) * 2009-08-14 2011-02-17 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides

Also Published As

Publication number Publication date
IL232781A0 (en) 2014-07-31
SG11201402661TA (en) 2014-08-28
CA2856967A1 (en) 2013-06-06
AU2012346058A1 (en) 2014-06-12
US20140364362A1 (en) 2014-12-11
WO2013082116A1 (en) 2013-06-06
MX2014006391A (es) 2014-09-22
KR20140103985A (ko) 2014-08-27
JP2014534265A (ja) 2014-12-18
EP2785367A1 (en) 2014-10-08
EP2785367A4 (en) 2015-06-17
CN104080473A (zh) 2014-10-01
US20130150291A1 (en) 2013-06-13
RU2014126244A (ru) 2016-01-27
BR112014012789A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
HK1202067A1 (en) Therapeutic agents comprising insulin amino acid sequences
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
WO2012168430A3 (en) Polypeptides
NZ705370A (en) Fcγriib-specific fc region variant
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
NZ812025A (en) Polypeptide variants and uses thereof
ECSP12011787A (es) Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
TN2014000134A1 (en) Therapeutic peptides
IN2012DN00971A (enExample)
PH12014500685B1 (en) Treatment of degenerative joint disease
WO2012006014A3 (en) Multi-component pharmaceuticals for treating diabetes
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2013014677A8 (en) Matrix compositions for controlled release of peptide and polypeptide molecules
HK1202811A1 (en) Compositions for preventing or treating adverse reactions of egfr inhibition
WO2012076961A3 (en) Carnosine - hyaluronic acid mixtures and their use
AU2010353685A8 (en) Novel glucagon like peptide analogs, composition, and method of use
WO2014039074A3 (en) Therapeutic compositions and related methods
BRPI1015042A2 (pt) unidades desencadeadoras ácido-lábeis
MY163470A (en) Curing process for concrete
EP2588080A4 (en) INJECTABLE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF JOINTS
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2013037985A8 (en) Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
MX2012009537A (es) Formas solidas que comprenden un derivado de ciclopropilamida.
ZA201105821B (en) Pharmaceutical composition containing l-ribozyme for treating adverse reactions by administering spiegelmers

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: PRIOR, CHRISTOPHER